Newark, Delaware – Nicholas (Nic) Dracopoli, Ph.D, an experienced leader in oncology translation research, biomarkers and diagnostics has joined GenPro’s Scientific Advisory Board as the outside lead.
According to Nic, “What captured my interest is GenPro’s science and technology’s ability to rapidly discover a powerful new category of phenotypic biomarkers based on epigenetic responses to different cancers and diseases. There is a huge unmet clinical need in the exploding immuno-oncology field and across the disease spectrum for precision biomarkers that mutation markers cannot easily address. GenPro’s immune-system derived EpiMarkers are well positioned to exploit this opportunity.”
Jeb Connor, GenPro’s Chairman, CEO and Co-founder conveyed, “We are excited by Nic’s decision to participate in and help advance GenPro. He brings a wealth of experience, expertise, and leading-edge knowledge at the nexus of immuno-oncology, biomarker science and commercialization, and patient care to influence and guide our strategy execution.”
Until January 2019, Nic was Senior Vice President of Translational Sciences at Personal Genome Diagnostics (PGDx) for one year after eighteen years working in oncology drug development at Bristol Myers-Squibb (BMS) and Janssen Pharmaceuticals. In these roles, he was responsible for building two new translational science teams whose work contributed to the approval of several new oncology drugs for BMS and Janssen. Prior to leaving Janssen Nic was Vice President, Head of Oncology Diagnostics and Vice President, Head of Oncology Translation Research. Prior to joining the pharmaceutical industry, he spent five years in the biotechnology industry at Sequana Therapeutics. Nic obtained his bachelor’s degree and doctorate from the University of London and completed post-doctoral fellowships at the Memorial Sloan-Kettering Cancer Center in New York City, NY and the Massachusetts Institute of Technology (MIT) in Cambridge, MA. Subsequently, he served as an Assistant Director at the Whitehead/MIT Genome Center and as a Section Chief at the National Center for Human Genome Research at the National Institutes of Health, Bethesda, MD. Nic has authored more than 70 scientific publications and has extensive experience in the fields of genomics, molecular biology and cancer research.
About GenPro – Powered by a proprietary machine-learning bioinformatics platform, GenPro is “decoding” the immune system to rapidly discover (< 10 weeks) a new class of predictive biomarkers – blood-based, immune-system-derived biomarkers called EpiMarkers. EpiMarkers are patentable, translate into clinical tests and are proving to be better, faster and less costly than gene mutation biomarkers. Each EpiMarker discovery illuminates broad, new, clinically actionable immuno-cellular information beyond what other biomarkers provide. Novel EpiMarkers are demonstrating excellent success across many diseases, sample types and applications for pre-treatment identification of responders vs non-responders to therapeutics, early disease detection, therapeutic efficacy monitoring, and diagnostics.
Contacts: For more information via email GenPro at: email@example.com